Abeona therapeutics provides regulatory update on pz-cel

Receives fda complete response letter (crl) based on need for additional cmc information crl did not identify deficiencies related to clinical efficacy or clinical safety data in bla, and no new clinical studies requested by fda to support approval anticipates completing and submitting requested cmc information in 3q 2024 conference call and webcast on tuesday, april 23, 2024 at 8:30 a.m. et to provide details on the requested cmc information cleveland, april 22, 2024 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced a regulatory update for prademagene zamikeracel (pz-cel).
ABEO Ratings Summary
ABEO Quant Ranking